Amgen Reports Initiation of Second P-III METEORIC-HF Study of Omecamtiv Mecarbil for Patients with Heart Failure

 Amgen Reports Initiation of Second P-III METEORIC-HF Study of Omecamtiv Mecarbil for Patients with Heart Failure

Amgen Reports Initiation of Second P-III METEORIC-HF Study of Omecamtiv Mecarbil for Patients with Heart Failure

Shots:

  • The P-III METEORIC-HF study involves assessing of omecamtiv mecarbil (25/50 mg, bid) vs PBO in 270 patients in the ratio (2:1) on exercise capacity as determined by cardiopulmonary exercise testing (CPET) with HFrEF at sites throughout the US, Canada and EU
  • In 2006, Amgen & Cytokinetics collaborated to develop therapeutics for the activation of cardiac sarcomere for heart failure. The second P-III METEORIC-HF Study is conducted by Cytokinetics in collaboration with Amgen and to be fund by Servier
  • Omecamtiv Mecarbil is a cardiac muscle activator evaluated in global P-III GALACTIC-HF study versus PBO for patients with heart failure or have had a hospitalization or admission to an emergency room for heart failure within one year prior to screening

Click here to read full press release/ article | Ref: Amgen | Image: Twitter


Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post